CRP level not helpful in predicting breast cancer

Article

While researchers have surmised that chronic inflammation is associated with an increased risk for breast cancer, a recent study suggests that baseline plasma C-reactive protein (CRP)-a marker of systemic inflammation-is not associated with an increased risk for the disease in otherwise healthy women.

While researchers have surmised that chronic inflammation is associated with an increased risk for breast cancer, a recent study suggests that baseline plasma C-reactive protein (CRP)-a marker of systemic inflammation-is not associated with an increased risk for the disease in otherwise healthy women.

Researchers included almost 28,000 healthy women aged 45 years and older participating in the Women's Health Study. During a mean follow-up of 10 years, almost 900 women developed invasive breast cancer; however, baseline plasma CRP level was not associated with breast cancer risk (highest vs. lowest quintile of CRP, multivariable HR 0.90; 95% CI, 0.71–1.16; P=0.19).

Zhang SM, Lin J, Cook NR, et al. C-reactive protein and risk of breast cancer. J Natl Cancer Inst. 2007;99:890-894.

Related Videos
Understanding combined oral contraceptives and breast cancer risk | Image Credit: health.ucdavis.edu
Why doxycycline PEP lacks clinical data for STI prevention in women
The importance of nipocalimab’s FTD against FNAIT | Image Credit:  linkedin.com
Enhancing cervical cancer management with dual stain | Image Credit: linkedin.com
Fertility treatment challenges for Muslim women during fasting holidays | Image Credit: rmanetwork.com
Understanding the impact of STIs on young adults | Image Credit: providers.ucsd.edu.
CDC estimates of maternal mortality found overestimated | Image Credit: rwjms.rutgers.edu.
Study unveils maternal mortality tracking trends | Image Credit: obhg.com
How Harmonia Healthcare is revolutionizing hyperemesis gravidarum care | Image Credit: hyperemesis.org
Unveiling gender disparities in medicine | Image Credit:  findcare.ahn.org.
Related Content
© 2024 MJH Life Sciences

All rights reserved.